Its lead commercial product, PrecivityAD™, is a mass spectrometry-based test that measures in blood multiple analytes including Aβ42, Aβ40, and apolipoprotein E isoforms. This test predicts brain amyloid plaques as determined by PET scan results and in 2019 it received a Breakthrough Device Designation from the U.S. Diagnostic efforts revolve around bringing accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring. It focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. TheScientist selected it as one of the biggest science news stories of the year.Ĭ₂ N’s Diagnostics’ vision is to bring Clarity Through Innovation™. MedPage Today named it one of its 2020 big breakthroughs. Princeton Magazine included the test in its round-up of medical research and scientific lab successes. NBC News put the PrecivityAD™ blood test on its list of top 2020 medical accomplishments. Howard Fillit, MD, the founding executive director and chief science officer of ADDF, says, “the fact that there is now an Alzheimer’s blood test on the market is just amazing.” The following are just a sampling of the recognition C₂N Diagnostics has received for its efforts:Īlzheimer’s Drug Discovery Foundation (ADDF) named the PrecivityAD™ blood test one of its top five highlights of 2020. The company is continuing to pursue CLIA lab certification from the remaining states of Maryland, New York and Pennsylvania and expects to achieve them soon. These features make the test more accessible than other diagnostic methods that physicians use to evaluate issues with memory and thinking.īreakthrough Receives Important Recognition
The PrecivityAD™ test does not involve any radiation exposure and is non-invasive.
The test is only available through an order by a clinician. The PrecivityAD™ test is intended for use in individuals experiencing memory and thinking issues. The test relies on precise quantitation of the amyloid beta 42/40 ratio (Aβ 42/40) and detection of the apolipoprotein E proteotype (equivalent to ApoE genotype) in blood samples, using C₂N’s proprietary mass spectrometry platform. The PrecivityAD™ test identifies whether a patient is likely to have amyloid plaques in the brain. PrecivityAD™ Blood Test Relies on Proprietary Platform To date, we have received positive feedback from physicians and patients about the test and its effectiveness.” They have all eagerly awaited innovative tools to address the challenges of cognitive health and Alzheimer’s disease. Braunstein, MD, CEO of C₂N, says, “The expansion of the PrecivityAD™ blood test to Rhode Island is an important milestone as we continue to introduce this new option for patients, families and the medical community. In addition, the company is partnering with the state’s leading health care providers in additional research about the PrecivityAD™ blood test. Rhode Island has joined 46 other states, the District of Columbia and Puerto Rico in granting C₂N Diagnostics a CLIA certificate to conduct such testing. ApC₂N Diagnostics, which offers the first widely accessible blood test to help physicians with Alzheimer’s disease diagnosis, announces that Rhode Island physicians can now use PrecivityAD™ to aid in the evaluation of their patients showing cognitive impairment.
0 kommentar(er)
